Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Side effects

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  Next»
    Study title: "Amiodarone therapy in children: efficacy and side effects. - Vignati G et al. - 1985 (G. Ital. Cardiol., 15: 786-794) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" "Amiodarone therapy in children: efficacy and side effects. - Vignati G et al. - 1985 (G. Ital. Cardiol., 15: 786-794) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45225
    Study title: "Long term follow up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. - Guccione P et al. - 1990 (J. Am. Coll. Cardiol., 15: 1118-1124) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CE" "Long term follow up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. - Guccione P et al. - 1990 (J. Am. Coll. Cardiol., 15: 1118-1124) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CE"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45179
    Study title: "Optimal management o f amiodarone therapy: efficacy and side effects. - Hilleman D et al. - 1998 (Pharmacother., 18 (6 Pt 2): 138S-145S) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" "Optimal management o f amiodarone therapy: efficacy and side effects. - Hilleman D et al. - 1998 (Pharmacother., 18 (6 Pt 2): 138S-145S) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45184
    Study title: Higher frequency of early local side effects with aqueous versus depot immunotherapy for Hymenoptera venom allergy
    Active substance: APIS MELIFERA-LYOPHILISED BEE VENOM
    Study summary document link (including results):
    View full study record
    Document reference: 21824
    Study title: Higher frequency of early local side effects with aqueous versus depot immunotherapy for Hymenoptera venom allergy
    Active substance: Apis mellifera / Vespula spp.
    Study summary document link (including results):
    View full study record
    Document reference: 39790
    Study title: Report/protocol/study N°: Controlled clinical study of ZY 15021 Investigator: C. Pulino Report date: 5 May 1986 Design: randomized, single-blind, comparative Objective: evaluation of efficacy and safety of ZY 15021 used with antibiotics Population: subjects with laryngo-pharyngo-tonsillar disorders Evaluations: pharyngeal pain, pain in swallowing, dysphonia, oropharyngeal inflammation; side effects Total (verum; comparator): 28 (14, 14) Age (mean, range): 13-57 years
    Active substance: BENZOXONIUM CHLORIDE/BENZOXONIUM AND LIDOCAINE
    Study summary document link (including results):
    View full study record
    Document reference: 22304
    Study title: Report/protocol/study N°: Controlled clinical study of ZY 15021 Investigator: G. Sambuco Report date: 24 Jul 1986 Design: randomized, single-blind, comparative Objective: to compare the characteristics of ZY 15021 with those of cetylpyridinium chloride Population: patients with recurrent pharyngitis-laryngitis, post-surgical oropharynx inflammation Evaluations: pharyngeal pain, difficulty swallowing, dysphonia, inflammation; side effects Age (mean, range): 12-74 years (no details provided)
    Active substance: BENZOXONIUM CHLORIDE/BENZOXONIUM AND LIDOCAINE
    Study summary document link (including results):
    View full study record
    Document reference: 22303
    Study title: Report/protocol/study N°: Clinical study on ZY 15021 Investigator: C. Galletti Report date: 30 Apr 1986 Design: open, non comparative Objective: evaluation of therapeutic efficacy and safety of ZY 15021 gelsolets, solution, oral spray Population: subjects with laryngo-pharyngo-tonsillar disorders with throat pain Evaluations: clinical symptoms, side effectsPeloso U.C. et al.: Penicillin concentrations in sera and tonsils after intramuscolar administration of benzathine penicillin G to children. Pediat.lnfect.Dis.J. 2003;22(12):1075-8
    Active substance: BENZENTHONIUM AND LIDOCAINE
    Study summary document link (including results):
    View full study record
    Document reference: 22284
    Study title: Report/protocol/study N°: Clinical trial of Orofar Investigator: A. Monteverde Report date: 18 Sep 1986 Design: open, non comparative Objective: Evaluation of efficacy and safety of Orofar gelsolets Population: subjects with acute pharyngitis or tonsillitis Evaluations: body temperature, pharyngeal pain, swallowing difficulties, dysphonia, inflammation, side effects
    Active substance: BENZENTHONIUM AND LIDOCAINE
    Study summary document link (including results):
    View full study record
    Document reference: 22283
    Study title: Report/protocol/study N°: Controlled clinical study of ZY 15021 Investigator: C. Pulino Report date: 5 May 1986 Design: randomized, single-blind, comparative Objective: evaluation of efficacy and safety of ZY 15021 used with antibiotics Population: subjects with laryngo-pharyngo-tonsillar disorders Evaluations: pharyngeal pain, pain in swallowing, dysphonia, oropharyngeal inflammation; side effects
    Active substance: BENZENTHONIUM AND LIDOCAINE
    Study summary document link (including results):
    View full study record
    Document reference: 22280
    Study title: Report/protocol/study N°: Controlled clinical study of ZY 15021 Investigator: G. Sambuco Report date: 24 Jul 1986 Design: randomized, single-blind, comparative Objective: to compare the characteristics of ZY 15021 with those of cetylpyridinium chloride Population: patients with recurrent pharyngitis-laryngitis, post-surgical oropharynx inflammation Evaluations: pharyngeal pain, difficulty swallowing, dysphonia, inflammation; side effects
    Active substance: BENZENTHONIUM AND LIDOCAINE
    Study summary document link (including results):
    View full study record
    Document reference: 22279
    Study title: Report/protocol/study N°: Clinical study on ZY 15021 Investigator: C. Galletti Report date: 30 Apr 1986 Design: open, non comparative Objective: evaluation of therapeutic efficacy and safety of ZY 15021 gelsolets, solution, oral spray Population: subjects with laryngo-pharyngo-tonsillar disorders with throat pain Evaluations: clinical symptoms, side effects Total: 26 - gelsolets: 10 subjects - solution: 9 subjects - spray: 7 subjects Age (mean, range): 6-54 year
    Active substance: BENZOYL PEROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 22308
    Study title: Report/protocol/study N°: Clinical trial of Orofar Investigator: A. Monteverde Report date: 18 Sep 1986 Design: open, non comparative Objective: Evaluation of efficacy and safety of Orofar gelsolets Population: subjects with acute pharyngitis or tonsillitis Evaluations: body temperature, pharyngeal pain, swallowing difficulties, dysphonia, inflammation, side effects Total: 20 Age (mean, range): 13-82 years
    Active substance: BENZOYL PEROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 22307
    Study title: Effects of anesthetic technique on side effects associated with fentanyl Oralet premedication; Journal of Clinical Anesthesia 1997, 9(5): 374-8
    Active substance: FENTANYL
    Study summary document link (including results):
    View full study record
    Document reference: 27144
    Study title: Determination of an effective dose of fenoterol, as free as possible from side effects for regular therapeutic use in obstructive respiratory tract diseases.
    Active substance: FENOTEROL
    Study summary document link (including results): Fenoterol hydrobromide_U83-0224_synopsis.pdf
    View full study record
    Document reference: 27087
    Study title: Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis
    Active substance: CETIRIZINE
    Study summary document link (including results):
    View full study record
    Document reference: 23711
    Study title: Central nervous system side effects of first- and second- generation antihistamines in school children with perennial allergic rhinitis: A randomized, double blind, placebo. Controlled comparative study
    Active substance: CHLORPHENAMINE AND PARACETAMOL
    Study summary document link (including results):
    View full study record
    Document reference: 24044
    Study title: Side effects with use of oral transmucosal fentanyl; Pediatrics, 1995, 96(3 Pt 1): 544
    Active substance: FENTANYL
    Study summary document link (including results):
    View full study record
    Document reference: 27181
    Study title: Central nervous system side effects of first- and second- generation antihistamines in school children with perennial allergic rhinitis: A randomized, double blind, placebo. Controlled comparative study
    Active substance: CHLORPHENAMINE AND TRAMAZOLINE
    Study summary document link (including results):
    View full study record
    Document reference: 24060
    Study title: Benesch M et al Outcome and long-term side effects after synchronous radiochemotherapy forchildhood brain stem gliomas Pediatr Neurosurg. 2001 Oct;35(4):173-80Benesch M et al Outcome and long-term side effects after synchronous radiochemotherapy forchildhood brain stem gliomas Pediatr Neurosurg. 2001 Oct;35(4):173-80
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 24766
    1  2  3  4  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 12:19:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA